Discovers and develops immuno-modulatory antibodies for cancer treatment. Focuses on therapies that harness the body's immune system to fight cancer. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 85% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 9.3× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 85% a year on average.
Sales run at $23.3M a year. A small number, but proof the product has real buyers.
A loss of $34.3M against $23.3M in annual sales.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.